Alere Inc (ALR) 35.75 $ALR
Alere Upped to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 4:20PM CDT
Alere has delivered positive earnings surprises in all of the last 4 quarters with an average beat of 27.6%.
Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro
Chembio Terminates U.S. Distribution Agreement With Alere
GlobeNewswire - Mon Apr 07, 9:00AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, announced today that it notified Alere Inc., formerly Inverness Medical Innovations, Inc. ("Alere" , of termination of its U.S. STAT-PAK(R) distribution agreement.
Earnings Release Schedules, Study Publications, and Annual Report Filing Updates - Analyst Notes on Align, Alere, Haemonetics, Hanger, and Hill-Rom
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology Inc. (NASDAQ: ALGN), Alere Inc. (NYSE: ALR), Haemonetics Corp. (NYSE: HAE), Hanger Inc. (NYSE: HGR), and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018
M2 - Fri Apr 04, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cd9kt8/pointofcare) has announced the addition of the "Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018" report to their offering. The global point-of-care diagnostics market is dominated by North America, followed by Europe, Asia-Pacific and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period, followed by the Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR of -13.6% from 2013 to 2018. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as the huge patient population base, increasing funding/investment toward the development of point of care diagnosticproducts, growing focus of both international and domestic players on the Asia-Pacific point-of-care diagnostics market, and large number of R&D activities are driving the growth of the market in the Asia-Pacific region. A number of factors such as the rising prevalence of lifestyle and infectious diseases, increasing usage of home-based POC devices, and decreasing number of technicians in central labs are driving the growth of the global market. Furthermore, growing government support and increasing private investments and venture funding to support new product development are other factors that are propelling the growth of the market. In addition, rising adoption of POC devices, expansion of therapeutic horizon, and technological advancements is further fueling the growth of this market. However, a few pivotal factors such as lack of alignment with definitive central lab methods, and reluctance to change existing treatment practices are hindering the growth of this market. Moreover, disadvantages of POC testing over central lab methods and recalls of leading glucose monitoring devices are the foremost challenges faced by industry players. New product launches is the key strategy followed by leading market players to ensure their growth in the POC diagnostics market. Moreover, partnerships, agreements, collaboration, and joint ventures; mergers and acquisitions; and expansions are some other growth strategies adopted by industry players in the global market. Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Trends - Point-Of-Care Diagnostics Market, By Product - Point-Of-Care Diagnostics Market, By Prescription Mode - Point-Of-Care Diagnostics Market, By End User - Point-Of-Care Diagnostics Market, By Geography - Competitive Landscape - Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Bayer Healthcare Ag - Beckman Coulter, Inc. - Becton, Dickinson And Company - Johnson & Johnson - Nipro Diagnostics, Inc. - Roche Diagnostics Limited - Siemens Healthcare Visit http://www.researchandmarkets.com/research/cd...ointofcare
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alere Shares Vision on How Population Analytics Can Help Improve Outcomes in a Complimentary Webinar from the Population Health Alliance
Business Wire - Tue Mar 25, 7:25AM CDT
Alere Analytics, an Alere subsidiary specializing in analytics and clinical decision support (CDS) technology, today announced that Chief Medical Officer and Co-founder, Dr. Fauzia Khan will lead a webinar discussion on April 2, 2014 at 1:00 PM that highlights how population analytics can help improve outcomes for patients, providers and payers. Dr. Khan's webinar is a part of Population Health Alliance's (PHA) complimentary Accountable Care Organization (ACO) & Provider Webinar Series titled, "How Population Health Improvement Can Benefit Providers and ACOs."
Weekly Coagulation Self-testing among Warfarin Patients Significantly Improves Outcomes, According to Study Published in the American Journal of Managed Care
PR Newswire - Mon Mar 24, 8:12AM CDT
Alere Inc. (NYSE: ALR) today announced the publication of the largest-ever study of warfarin patient self-testing, which demonstrated that weekly International Normalized Ratio (INR) testing significantly improves control of warfarin, as measured by time in therapeutic range (TTR), versus a variable testing frequency. Results of the Self-Testing Analysis Based on Long-Term Experience (STABLE) study, which was supported by Alere, were published today in The American Journal of Managed Care.
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017
M2 - Tue Mar 11, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nc4zfn/in_vitro) has announced the addition of the "Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017" report to their offering. The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, the IVD market has segments like instruments, reagents, data management software/hardware, and services. Based on applications, the in vitro diagnostic market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market. The global in vitro diagnostic market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. The IVD market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global In Vitro Diagnostic Market, By Technique 5 Global In Vitro Diagnostic Market, By Product Type 6 Global In Vitro Diagnostic Market, By Application 7 Global In Vitro Diagnostic Market, By End-User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - Alere, Inc - Arkray, Inc - Bayer AG - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc - Biomerieux - Danaher Corporation - Diagnostica Stago Sas - Diasorin SPA - Hologic, Inc - Horiba, Ltd - Johnson & Johnson - Novartis International Ag - Qiagen NV - Roche Diagnostics Limited - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/nc4zfn/in_vitro
Coagulation Home Testing Improves Outcomes among Atrial Fibrillation Patients on Warfarin Therapy and Enhances Clinical Efficiency, According to New Study
PR Newswire - Tue Mar 04, 3:30PM CST
Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, today announced the results of a study demonstrating that at-home coagulation testing among atrial fibrillation patients receiving warfarin led to improved outcomes versus traditional self-testing management, as well as enhanced clinical efficiencies and reduced costs. Results of the study, which was supported by Alere, were published today in the current issue of the journal Nursing 2014.
Alere Inc. Declares Cash Dividend On Its Series B Convertible Perpetual Preferred Stock
PR Newswire - Mon Mar 03, 6:33PM CST
Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.
. The dividend is payable on April 15, 2014 to holders of record of Series B stock at the close of business on April 1, 2014.
Global Enteric Disease Testing Market 2014-2018: New Emerging Viruses and Bacteria Playing an Important Role in Diagnostics Industry
M2 - Wed Feb 26, 6:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrghlr/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018" report to their offering. The analysts forecast the Global Enteric Disease Testing market to grow at a CAGR of 2.83 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of enteric diseases. The Global Enteric Disease Testing market has also been witnessing the emergence of new pathogens causing infections. However, the stringent regulatory approval could pose a challenge to the growth of this market. Key vendors dominating this space are Alere Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Cepheid Inc. and DiaSorin S.p.A. Other vendors mentioned in the report are Affymetrix Inc., Beckton, Dickenson and Co., Biomerica Inc., Coris BioConcept, Danaher Corp., Meridian Bioscience Inc., Quest Diagnostics Inc., R-Biopharm AG, and Trinity Biotech PLC. Commenting on the report, an analyst from the team said: Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. According to the report, one of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. For more information visit http://www.researchandmarkets.com/research/lr...al_enteric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alere to Attend Upcoming Financial Conferences
PR Newswire - Mon Feb 24, 3:30PM CST
Alere Inc. (NYSE: ALR), the world's leading provider of point-of-care rapid diagnostic and health information solutions, announced today that it will attend three separate financial conferences over the next two weeks. Jon Russell, Vice President, Finance, will attend and present at all three events. Conference information and presentation schedule are as follows:
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Thursday
Alere to Showcase its Connected Health Technologies at HIMSS 2014
PR Newswire - Wed Feb 19, 7:30AM CST
Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health through the merger of rapid diagnostics and health information solutions, today announced that Alere will demonstrate its Connected Health technologies at the HIMSS 2014 Annual Conference to help providers, payers and accountable care organizations improve care coordination, identify gaps in care, and drive healthy patient behaviors. The conference, held at the Orange County Convention Center in Orlando, FL from February 23 - 27, 2014, brings together over 37,000 healthcare IT professionals, clinicians, executives and leading HIT companies from around the world. During the conference, Alere will be showcasing the Company's suite of Connected Health solutions at booth #5345.
Alere Earnings Beat, EPS Rises 20% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 10:00AM CST
For full year 2013, Alere revealed a 5.3% rise in net earnings to $2.19 per share from $2.08 per share a year ago
Alere (ALR) in Focus: Stock Tumbles 8.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:59AM CST
Alere Inc. (ALR) saw a big move last session, breaking the recent trend of the company, as the stock is now trading below the volatile price range of $35.67 to $33.99 in the past one-month time frame.
NYSE stocks posting largest volume increases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
Alere Upped to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 4:20PM CDT
Alere has delivered positive earnings surprises in all of the last 4 quarters with an average beat of 27.6%.
Global In-Vitro Toxicology/Toxicity Testing (Cell Culture, HTS, Omics) Market 2014-2018
M2 - Wed Apr 09, 9:08AM CDT
Research and Markets (http://www.researchandmarkets.com/research/59cs9d/invitro) has announced the addition of the "In-Vitro Toxicology/ Toxicity Testing Market by Industry, Technology, Applications & Method - Global Forecast to 2018" report to their offering. The global market of in-vitro toxicology testing is subdivided into industry, technology, method, application and geography. On the basis of industry, the market is further segmented into diagnostics, pharmaceuticals, chemicals, cosmetics, and food. Diagnostics is further categorized into sample and type. The largest market share was captured by the pharmaceutical industry, whereas cosmetics industry was the fastest growing industry with a double digit CAGR. The prime factor contributing to the growth of pharmaceutical industry has been the attention towards the detection of toxicity during earlier stages of development. On the basis of technology, the global market of in vitro toxicology testing is divided into cell culture, high throughput screening, cellular imaging, and omics technologies. Cell culture technology will witness the maximum growth rate in the coming years. The methods considered for the study are cellular assays, biochemical assays, ex vivo and in silico. Cellular assays market is estimated to grow at a double digit CAGR during the forecast period (2013-2018). Cellular assays can predict the biological properties of potential drug compounds. These assays can also detect and measure cell viability, functionality and growth. Under the applications, the market is segmented into systemic toxicity, dermal toxicity, ocular toxicity, endocrine disruption (reproductive & developmental toxicity) and others. Systemic toxicity testing was the largest segment in 2013. The increasing focus on detection of toxicity in earlier stages of development is leading to persistent requirement for human cell-based in vitro models for cardiotoxicity and liver toxicity testing which are the major reasons for drug attrition. Europe commanded the largest share of the global market in 2013. This is attributed to the support provided by the European government for anti-animal testing laws. The government has further put ban on the production and sale of all animal tested cosmetics across the continent. The market will be driven by increasing acceptance of in-vitro toxicology testing methods as alternatives to in vivo toxicology testing. The new technologies in the in vitro testing market help in investigating the adverse effects of environmental agents in a more mechanistic and time saving manner. Organizations such as REACH foresee that more results of in vitro and in silico methods will be included in risk assessment which will promote the use of in vitro methods for toxicology testing. Scope Industry - Diagnostic - Pharmaceutical - Cosmetics - Chemical Technology - Cell Culture - HTS - Omics Applications - Systemic - Dermal - Ocular Method - Cellular Assay - Ex vivo - In Silico Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - By Industry - By Technology - By Application - By Method - Geographic Analysis - Competitive Landscape - Company Profiles - Agilent Technologies, Inc. - Alere, Inc. - Bio-Rad Laboratories, Inc. - Bioreliance, Inc. - Catalent - Charles River Laboratories International, Inc. - Covance, Inc. - Cyprotex - Eurofins Scientific - GE Healthcare - Life Technologies Corporation - Quest Diagnostics Visit http://www.researchandmarkets.com/research/59cs9d/invitro
Chembio Terminates U.S. Distribution Agreement With Alere
GlobeNewswire - Mon Apr 07, 9:00AM CDT
Chembio Diagnostics, Inc. (Nasdaq:CEMI) a leader in point-of-care ("POC"
diagnostic tests for infectious diseases, announced today that it notified Alere Inc., formerly Inverness Medical Innovations, Inc. ("Alere" , of termination of its U.S. STAT-PAK(R) distribution agreement. Earnings Release Schedules, Study Publications, and Annual Report Filing Updates - Analyst Notes on Align, Alere, Haemonetics, Hanger, and Hill-Rom
PR Newswire - Mon Apr 07, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology Inc. (NASDAQ: ALGN), Alere Inc. (NYSE: ALR), Haemonetics Corp. (NYSE: HAE), Hanger Inc. (NYSE: HGR), and Hill-Rom Holdings, Inc. (NYSE: HRC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018
M2 - Fri Apr 04, 6:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cd9kt8/pointofcare) has announced the addition of the "Point-Of-Care Diagnostic Market Forecasts & Opportunities, 2018" report to their offering. The global point-of-care diagnostics market is dominated by North America, followed by Europe, Asia-Pacific and the Rest of the World (RoW). North America will continue to dominate the market in the forecast period, followed by the Asia-Pacific. However, the Asia-Pacific region is expected to grow at the highest CAGR of -13.6% from 2013 to 2018. Over the next five years, the growth of the market in the Asia-Pacific region is likely to be centered at Japan, China, and India. A number of factors such as the huge patient population base, increasing funding/investment toward the development of point of care diagnosticproducts, growing focus of both international and domestic players on the Asia-Pacific point-of-care diagnostics market, and large number of R&D activities are driving the growth of the market in the Asia-Pacific region. A number of factors such as the rising prevalence of lifestyle and infectious diseases, increasing usage of home-based POC devices, and decreasing number of technicians in central labs are driving the growth of the global market. Furthermore, growing government support and increasing private investments and venture funding to support new product development are other factors that are propelling the growth of the market. In addition, rising adoption of POC devices, expansion of therapeutic horizon, and technological advancements is further fueling the growth of this market. However, a few pivotal factors such as lack of alignment with definitive central lab methods, and reluctance to change existing treatment practices are hindering the growth of this market. Moreover, disadvantages of POC testing over central lab methods and recalls of leading glucose monitoring devices are the foremost challenges faced by industry players. New product launches is the key strategy followed by leading market players to ensure their growth in the POC diagnostics market. Moreover, partnerships, agreements, collaboration, and joint ventures; mergers and acquisitions; and expansions are some other growth strategies adopted by industry players in the global market. Key Topics Covered: - Introduction - Executive Summary - Premium Insights - Market Overview - Industry Trends - Point-Of-Care Diagnostics Market, By Product - Point-Of-Care Diagnostics Market, By Prescription Mode - Point-Of-Care Diagnostics Market, By End User - Point-Of-Care Diagnostics Market, By Geography - Competitive Landscape - Company Profiles - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Bayer Healthcare Ag - Beckman Coulter, Inc. - Becton, Dickinson And Company - Johnson & Johnson - Nipro Diagnostics, Inc. - Roche Diagnostics Limited - Siemens Healthcare Visit http://www.researchandmarkets.com/research/cd...ointofcare
Global Molecular Diagnostics Market 2012-2016: Trends and Collaborations Discussed
M2 - Fri Mar 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mchzgs/global_molecular) has announced the addition of the "Global Molecular Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Molecular Diagnostics market to grow at a CAGR of 11.42 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing investments in genomics and proteomics research. The Global Molecular Diagnostics market has also been witnessing a growth in the diagnostics segment. However, the compliance with regulatory requirements could pose a challenge to the growth of this market. Key vendors dominating this space include Abbott Laboratories, Becton, Dickinson and Co., QIAGEN N.V., and Roche Holding Ltd. Other vendors mentioned in the report are Affymetrix Inc., Agilent Technologies Inc., Alere Inc., AmniSure International LLC, Anadys Pharmaceuticals Inc., Bayer HealthCare AG, Biocartis SA, bioMerieux SA, Bio-Rad Laboratories Inc., Biotest AG, Carmel Pharma AB, Celera Diagnostics LLC, Cellestis Ltd., Cepheid Inc., Cytometers Inc., Danaher Corp., Diagenode SA, Eli Lilly and Co., Eurogentec S.A., Evotec AG, GE Healthcare Ltd., Genomic Health Inc., Gen-Probe Inc., Illumina Inc., Instrumentation Laboratory Co., IRIS International Inc., Janssen Biotech Inc., KIESTRA Lab Automation BV, Life Technologies Corp., Luminex Corp., Merck and Co. Inc., mtm laboratories AG, Nanosphere Inc., Novartis AG, PerkinElmer Inc., Pharmacyclics Inc., PVT Probenverteiltechnik GmbH, Quest Diagnostics Inc., Quidel Corp., Safety Syringes Inc., SANYO North America Corp., Siemens Healthcare, Sirigen Group Limited, St. Jude Medical Inc., Sysmex Corp., and Thermo Fisher Scientific Inc. Commenting on the report, an analyst from the Healthcare team said: 'The Global Molecular Diagnostics market presents several growth opportunities to vendors. Different vendors in the market are increasingly forming strategic alliances with pharmaceutical companies for the development of companion diagnostics, which helps in producing more effective drugs. For instance, in February 2013, Abbott Laboratories collaborated with Janssen Biotech Inc. and Pharmacyclics Inc. to discover the benefits of Abbott's exclusive FISH technology for use in developing a molecular companion diagnostic test to identify patients with chronic lymphocytic leukemia. For more information visit http://www.researchandmarkets.com/research/mc..._molecular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alere Shares Vision on How Population Analytics Can Help Improve Outcomes in a Complimentary Webinar from the Population Health Alliance
Business Wire - Tue Mar 25, 7:25AM CDT
Alere Analytics, an Alere subsidiary specializing in analytics and clinical decision support (CDS) technology, today announced that Chief Medical Officer and Co-founder, Dr. Fauzia Khan will lead a webinar discussion on April 2, 2014 at 1:00 PM that highlights how population analytics can help improve outcomes for patients, providers and payers. Dr. Khan's webinar is a part of Population Health Alliance's (PHA) complimentary Accountable Care Organization (ACO) & Provider Webinar Series titled, "How Population Health Improvement Can Benefit Providers and ACOs."
Weekly Coagulation Self-testing among Warfarin Patients Significantly Improves Outcomes, According to Study Published in the American Journal of Managed Care
PR Newswire - Mon Mar 24, 8:12AM CDT
Alere Inc. (NYSE: ALR) today announced the publication of the largest-ever study of warfarin patient self-testing, which demonstrated that weekly International Normalized Ratio (INR) testing significantly improves control of warfarin, as measured by time in therapeutic range (TTR), versus a variable testing frequency. Results of the Self-Testing Analysis Based on Long-Term Experience (STABLE) study, which was supported by Alere, were published today in The American Journal of Managed Care.
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017
M2 - Tue Mar 11, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nc4zfn/in_vitro) has announced the addition of the "Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017" report to their offering. The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, the IVD market has segments like instruments, reagents, data management software/hardware, and services. Based on applications, the in vitro diagnostic market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market. The global in vitro diagnostic market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. The IVD market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global In Vitro Diagnostic Market, By Technique 5 Global In Vitro Diagnostic Market, By Product Type 6 Global In Vitro Diagnostic Market, By Application 7 Global In Vitro Diagnostic Market, By End-User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - Alere, Inc - Arkray, Inc - Bayer AG - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc - Biomerieux - Danaher Corporation - Diagnostica Stago Sas - Diasorin SPA - Hologic, Inc - Horiba, Ltd - Johnson & Johnson - Novartis International Ag - Qiagen NV - Roche Diagnostics Limited - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/nc4zfn/in_vitro
Coagulation Home Testing Improves Outcomes among Atrial Fibrillation Patients on Warfarin Therapy and Enhances Clinical Efficiency, According to New Study
PR Newswire - Tue Mar 04, 3:30PM CST
Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, today announced the results of a study demonstrating that at-home coagulation testing among atrial fibrillation patients receiving warfarin led to improved outcomes versus traditional self-testing management, as well as enhanced clinical efficiencies and reduced costs. Results of the study, which was supported by Alere, were published today in the current issue of the journal Nursing 2014.
Alere Inc. Declares Cash Dividend On Its Series B Convertible Perpetual Preferred Stock
PR Newswire - Mon Mar 03, 6:33PM CST
Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.
. The dividend is payable on April 15, 2014 to holders of record of Series B stock at the close of business on April 1, 2014. Global Enteric Disease Testing Market 2014-2018: New Emerging Viruses and Bacteria Playing an Important Role in Diagnostics Industry
M2 - Wed Feb 26, 6:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrghlr/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018" report to their offering. The analysts forecast the Global Enteric Disease Testing market to grow at a CAGR of 2.83 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of enteric diseases. The Global Enteric Disease Testing market has also been witnessing the emergence of new pathogens causing infections. However, the stringent regulatory approval could pose a challenge to the growth of this market. Key vendors dominating this space are Alere Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Cepheid Inc. and DiaSorin S.p.A. Other vendors mentioned in the report are Affymetrix Inc., Beckton, Dickenson and Co., Biomerica Inc., Coris BioConcept, Danaher Corp., Meridian Bioscience Inc., Quest Diagnostics Inc., R-Biopharm AG, and Trinity Biotech PLC. Commenting on the report, an analyst from the team said: Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. According to the report, one of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. For more information visit http://www.researchandmarkets.com/research/lr...al_enteric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alere to Attend Upcoming Financial Conferences
PR Newswire - Mon Feb 24, 3:30PM CST
Alere Inc. (NYSE: ALR), the world's leading provider of point-of-care rapid diagnostic and health information solutions, announced today that it will attend three separate financial conferences over the next two weeks. Jon Russell, Vice President, Finance, will attend and present at all three events. Conference information and presentation schedule are as follows:
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Thursday
Alere to Showcase its Connected Health Technologies at HIMSS 2014
PR Newswire - Wed Feb 19, 7:30AM CST
Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health through the merger of rapid diagnostics and health information solutions, today announced that Alere will demonstrate its Connected Health technologies at the HIMSS 2014 Annual Conference to help providers, payers and accountable care organizations improve care coordination, identify gaps in care, and drive healthy patient behaviors. The conference, held at the Orange County Convention Center in Orlando, FL from February 23 - 27, 2014, brings together over 37,000 healthcare IT professionals, clinicians, executives and leading HIT companies from around the world. During the conference, Alere will be showcasing the Company's suite of Connected Health solutions at booth #5345.
Alere Earnings Beat, EPS Rises 20% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 10:00AM CST
For full year 2013, Alere revealed a 5.3% rise in net earnings to $2.19 per share from $2.08 per share a year ago
Alere (ALR) in Focus: Stock Tumbles 8.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:59AM CST
Alere Inc. (ALR) saw a big move last session, breaking the recent trend of the company, as the stock is now trading below the volatile price range of $35.67 to $33.99 in the past one-month time frame.
NYSE stocks posting largest volume increases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
